MS and Demyelinating Disorders

Data used from the ENSEMBLE PLUS study showed a comparable frequency of infusion reactions between those who received the 2-hour infusion and the 3.5-hour infusion.

Here's what is coming soon to NeurologyLive.

Stephen Krieger, MD, discusses a new phase 3 trial of nabiximols, which is now recruiting patients with MS.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending December 11, 2020.

No cognitive improvements were observed for exercise versus waitlist groups of cognitively normal patients with MS.

Further results of the 2 phase 3 studies are expected to be completed and presented in detail in first half of 2021, with a BLA submission to follow.

Here's what is coming soon to NeurologyLive.

Neurology News Network for the week ending December 5, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending December 4, 2020.

New analyses from the phase 2b SPRINT-MS trial suggest that MediciNova’s ibudilast (also known as MN-166), can lessen retinal thinning as measured by optical coherence tomography.

The largest cohort to explicitly summarize the pregnancy-related characteristics of NMOSD with different antibody subsets demonstrated higher rates of annualized relapse during first trimester after delivery or abortion.

Here's what is coming soon to NeurologyLive.

Two experts in neuro-ophthalmology discuss the advances in the identification and treatment of patients presenting with optic neuritis.

Guest editor-in-chief Darin T. Okuda, MD, FAAN, FANA, details the fast moving field of multiple sclerosis and the direction the disease is moving towards in 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending November 27, 2020.

The chair of the department of neurology at The Ohio State University spoke to the ongoing conversation in MS about how aggressive to be with treatment early on.

“Is more always better?”: The age-old question is more relevant than ever as clinicians and patients alike navigate an increasingly crowded MS treatment landscape.

Stephen Krieger, MD from the Icahn School of Medicine at Mount Sinai spoke about the phase 3 trial of nabiximols he will be investigating in MS.

Effectively navigating the nuances of this unique patient population will ultimately help drive innovative solutions for this generation and those to come.

As the adoption of telemedicine rises, the ability to incorporate digital and telehealth-based therapies offers clinicians a unique opportunity to supplement the comprehensive care model.

Advanced imaging technology collides with artificial intelligence in what is shaping up to be a revolutionary period for the diagnosis and management of MS.